 
                                    Japan is looking into the possibility of mixing shots of AstraZeneca Plc's COVID-19 vaccine with those developed by other drug makers in a bid to speed up its vaccine rollout, the minister in charge of vaccinations said on Sunday.
Japan, which has previously relied on the Pfizer-BioNTech and Moderna vaccines, approved AstraZeneca's vaccine in July and has secured two million doses.
"I have asked the health ministry to come up with an opinion about the use of AstraZeneca vaccines for the first dose and Pfizer's with the second, or the AstraZeneca's as the first shot and Moderna as second," vaccine programme chief Taro Kono said on the Fuji Television network.
This could speed up the vaccination rollout by shortening the intervals between the first and second shots when using the AstraZeneca vaccine, he said.
AstraZeneca's two shots are administered with an interval of eight weeks, longer than for the other vaccines.
Japan is battling its worst wave of infections, driven by the Delta variant, with new daily infections exceeding 25,000 this month for the first time.
The country's vaccination ratio has lagged other developed nations. Japan has inoculated 54 per cent of its population with at least one dose and fully vaccinated 43 per cent, according to a Reuters vaccine tracker.


 Trump-Putin summit cancelled, FT reports
            Trump-Putin summit cancelled, FT reports
         Hurricane Melissa leaves 49 dead in Caribbean, churns north
            Hurricane Melissa leaves 49 dead in Caribbean, churns north
         King Charles strips brother Andrew of titles and his mansion
            King Charles strips brother Andrew of titles and his mansion
         Vietnam flood death toll rises to 13, with 11 others missing
            Vietnam flood death toll rises to 13, with 11 others missing
         US grants India six-month sanctions waiver to run Iran's Chabahar port
            US grants India six-month sanctions waiver to run Iran's Chabahar port
         
                 
                 
                 
                